Abstract

ObjectiveLeukoaraiosis (LA), as an age‐related white matter degeneration, is mainly caused by chronic ischemia. Our study aims to explore the efficacy of different doses of atorvastatin (ATV) in the vascular endothelial function in patients with LA.MethodsOur study enrolled 402 LA patients who were then randomly included as control or treated with ATV (10 mg), ATV (20 mg), or ATV (30 mg). The total cholesterol (TC), triglycerides (TG), high‐density lipoprotein cholesterol (HDL‐C), and low‐density lipoprotein cholesterol (LDL‐C) were detected by enzyme colorimetric assay. The high‐sensitivity C‐reactive protein (hs‐CRP) level, reactive hyperemia index (RHI), endothelin‐1 (ET‐1) content, and nitric oxide (NO) level were tested by latex agglutination test, peripheral arterial tonometry technology, radioimmunoassay, and nitrate reductase assay, respectively.ResultsAfter 8 weeks of ATV treatment, the levels of TC, LDL‐C, and HS‐CRP decreased significantly, and the trends were demonstrated in a more significant way with the increases of dose of ATV. The treatment with ATV at different doses elevated NO level and RHI and declined ET‐1 content. Gastrointestinal reaction, muscular pain, and increased aminopherase were observed after treatment with the ATV at different doses with more obvious symptoms detected accompanied by the increase of the dose. The RHI was in negative correlation with the ET‐1 and HS‐CRP while in positive correlation with NO.ConclusionOur study demonstrates that ATV can significantly improve the vascular endothelial function in LA patients with a dose‐dependent effect.

Highlights

  • Leukoaraiosis (LA), or severity of white matter hyperintensity, is a crucial biomarker for cerebrovascular disease.[1]

  • Leukoaraiosis, or white matter changes, is in close association with increased age, history of stroke, hypertension, and diabetes melli‐ tus.[19]. It has been worldwide regarded as a part of the normal aging process, even though it is strongly associated with dementia or other disabilities, and its pathogenesis still has not been thoroughly ac‐ knowledged.[20]

  • Our study examined the association between different doses of ATV and vascular endothelial function in patients with LA, aimed at providing a better therapeutic procedure for LA treatment

Read more

Summary

| INTRODUCTION

| 2 of 9 characterized by declined nitric oxide (NO) bioavailability, was pres‐ ent as the first stage during the development of coronary artery dis‐ ease.[7]. This study aims to explore the role of ATV in the vascular endothelial function in patients with LA, so as to provide a therapeutic method for LA treatment

| Ethical statement
Findings
| DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call